Agenus (AGEN) Cash & Equivalents (2010 - 2026)
Agenus (AGEN) posted quarterly Cash & Equivalents of $35.0 million for Q1 2026, up 89.29% year-over-year from $18.5 million in Q1 2025, and up 1067.31% quarter-over-quarter from $3.0 million in Q4 2025.
Analysis
Agenus (AGEN) Cash & Equivalents (2010 - 2026) Analysis & Trends
Agenus' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $35.0 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 89.29% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $35.0 million (up 89.29% YoY), while the FY2025 annual figure was $3.0 million, down 92.59% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $35.0 million, up from $3.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $247.7 million in Q1 2022, with the low at $3.0 million in Q4 2025.
- The 5-year median for Cash & Equivalents is $76.1 million (2023), against an average of $97.3 million.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents soared 210.55% in 2022, then slumped 92.59% in 2025.
- Agenus' Cash & Equivalents stood at $178.7 million in 2022, then slumped by 57.4% to $76.1 million in 2023, then sank by 46.87% to $40.4 million in 2024, then plunged by 92.59% to $3.0 million in 2025, then soared by 1067.31% to $35.0 million in 2026.
- Business Quant data shows AGEN's Cash & Equivalents at $35.0 million in Q1 2026, $3.0 million in Q4 2025, and $3.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Agenus | 342.07 Mn | 342.07 Mn | 34.52 Mn | 18.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.74 Mn |
| Mar 31, 2026 | 35.00 Mn |
| Dec 31, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 9.53 Mn |
| Mar 31, 2025 | 18.49 Mn |
| Dec 31, 2024 | 40.44 Mn |
| Sep 30, 2024 | 44.78 Mn |
| Jun 30, 2024 | 93.72 Mn |
| Mar 31, 2024 | 52.86 Mn |
| Dec 31, 2023 | 76.11 Mn |
| Sep 30, 2023 | 106.31 Mn |
| Jun 30, 2023 | 143.21 Mn |
| Mar 31, 2023 | 164.82 Mn |
| Dec 31, 2022 | 178.67 Mn |
| Sep 30, 2022 | 208.35 Mn |
| Jun 30, 2022 | 228.39 Mn |
| Mar 31, 2022 | 247.71 Mn |
| Dec 31, 2021 | 291.93 Mn |
| Sep 30, 2021 | 256.53 Mn |